Akebia Therapeutics Inc. | Mutual Funds
Mutual Funds that own Akebia Therapeutics Inc.
Eagle Small Cap Growth Fund
2,060,804
3.61%
0
0.28%
06/29/2018
Vanguard Total Stock Market Index Fund
1,186,970
2.08%
0
0%
07/31/2018
SPDR S&P Biotech ETF
1,136,006
1.99%
2,922
0.16%
09/06/2018
iShares Russell 2000 ETF
1,055,193
1.85%
-564
0.02%
09/06/2018
Vanguard Extended Market Index Fund
710,211
1.25%
0
0.01%
07/31/2018
Fidelity Select Biotechnology Portfolio
674,878
1.18%
0
0.06%
07/31/2018
iShares Nasdaq Biotechnology ETF
655,957
1.14%
-8,568
0.06%
09/06/2018
Government Pension Fund - Global (The)
456,572
0.8%
456,572
0%
12/31/2017
iShares Russell 2000 Growth ETF
448,219
0.79%
0
0.03%
09/06/2018
Vanguard Variable Insurance - Small Company Growth Portfolio
347,727
0.61%
102,159
0.13%
06/30/2018
| Address |
245 First Street
Cambridge Massachusetts 02142
United States
|
|
Employees
|
- |
| Website |
http://www.akebia.com |
| Updated |
07/08/2019 |
| Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for hypoxia-inducible factor. It also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. It offers vadadustat, which is an oral therapy for the treatment of anemia due to chronic kidney disease. |
